Ligand Pharmaceuticals Incorporated (LGNYZ)
OTCMKTS · Delayed Price · Currency is USD
0.0400
0.00 (0.00%)
At close: May 22, 2025

Ligand Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
May '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Market Capitalization
1,9602,0251,2451,1282,5811,599
Upgrade
Market Cap Growth
56.42%62.59%10.35%-56.28%61.40%-12.69%
Upgrade
Enterprise Value
1,7561,8121,0611,1212,5891,264
Upgrade
Last Close Price
0.040.010.000.010.010.00
Upgrade
PE Ratio
--23.88-45.18-
Upgrade
PS Ratio
10.8012.119.485.7510.699.78
Upgrade
PB Ratio
2.462.441.781.893.142.25
Upgrade
P/TBV Ratio
4.504.424.188.117.85-
Upgrade
P/FCF Ratio
38.4821.2627.048.9936.8631.90
Upgrade
P/OCF Ratio
37.0820.8625.128.1932.7629.30
Upgrade
EV/Sales Ratio
9.6710.848.085.7110.727.73
Upgrade
EV/EBITDA Ratio
264.7531.1122.9027.1122.0918.31
Upgrade
EV/EBIT Ratio
-78.73108.04369.1139.0730.77
Upgrade
EV/FCF Ratio
34.4719.0323.048.9336.9625.22
Upgrade
Debt / Equity Ratio
0.010.010.010.150.400.64
Upgrade
Debt / EBITDA Ratio
0.230.120.132.092.746.42
Upgrade
Debt / FCF Ratio
0.090.080.130.704.639.11
Upgrade
Asset Turnover
0.200.190.170.190.180.11
Upgrade
Inventory Turnover
4.371.711.884.383.504.20
Upgrade
Quick Ratio
4.468.0512.492.5010.394.70
Upgrade
Current Ratio
5.278.9314.152.6711.155.00
Upgrade
Return on Equity (ROE)
-16.56%-0.53%8.29%-0.74%9.98%0.89%
Upgrade
Return on Assets (ROA)
-1.14%1.66%0.79%0.18%3.11%1.80%
Upgrade
Return on Capital (ROIC)
-1.29%1.86%0.88%0.21%3.58%1.99%
Upgrade
Return on Capital Employed (ROCE)
-2.50%1.30%0.50%5.30%3.30%
Upgrade
Earnings Yield
-6.77%-0.20%4.19%-2.96%2.21%-0.19%
Upgrade
FCF Yield
2.60%4.70%3.70%11.12%2.71%3.13%
Upgrade
Buyback Yield / Dilution
-4.84%-3.00%-5.27%2.19%-2.50%14.84%
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.